ECSP12011585A - Compuestos y composiciones para eltratamiento de enfermedades parasitarias - Google Patents

Compuestos y composiciones para eltratamiento de enfermedades parasitarias

Info

Publication number
ECSP12011585A
ECSP12011585A EC2012011585A ECSP12011585A ECSP12011585A EC SP12011585 A ECSP12011585 A EC SP12011585A EC 2012011585 A EC2012011585 A EC 2012011585A EC SP12011585 A ECSP12011585 A EC SP12011585A EC SP12011585 A ECSP12011585 A EC SP12011585A
Authority
EC
Ecuador
Prior art keywords
compounds
compositions
treatment
parasitary
diseases
Prior art date
Application number
EC2012011585A
Other languages
English (en)
Inventor
David C Tully
Arnab K Chatterjee
Advait Nagle
Tao Wu
Kelli L Kuhen
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011585(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of ECSP12011585A publication Critical patent/ECSP12011585A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

El invento proporciona una clase de compuestos y composiciones farmacéuticas que comprenden tales compuestos, y métodos para utilizar tales compuestos, para tratar o prevenir el paludismo.
EC2012011585A 2009-07-09 2012-01-09 Compuestos y composiciones para eltratamiento de enfermedades parasitarias ECSP12011585A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
ECSP12011585A true ECSP12011585A (es) 2012-02-29

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2012011585A ECSP12011585A (es) 2009-07-09 2012-01-09 Compuestos y composiciones para eltratamiento de enfermedades parasitarias

Country Status (38)

Country Link
US (3) US8557801B2 (es)
EP (2) EP2451814B1 (es)
JP (1) JP5432376B2 (es)
KR (1) KR101378666B1 (es)
CN (1) CN102471341B (es)
AR (1) AR077463A1 (es)
AU (1) AU2010271247B2 (es)
BR (1) BR112012000413B1 (es)
CA (1) CA2767664C (es)
CL (1) CL2012000042A1 (es)
CO (1) CO6491060A2 (es)
CR (1) CR20120008A (es)
CU (1) CU24155B1 (es)
DK (1) DK2451814T3 (es)
EA (1) EA019655B1 (es)
EC (1) ECSP12011585A (es)
ES (2) ES2477940T3 (es)
GT (1) GT201200004A (es)
HK (1) HK1164304A1 (es)
HN (1) HN2012000023A (es)
HR (1) HRP20140641T1 (es)
IL (1) IL217384A (es)
JO (1) JO3156B1 (es)
MA (1) MA33419B1 (es)
MX (1) MX2012000389A (es)
MY (1) MY157238A (es)
NZ (1) NZ597275A (es)
PE (1) PE20130399A1 (es)
PL (1) PL2451814T3 (es)
PT (1) PT2451814E (es)
SG (1) SG176938A1 (es)
SI (1) SI2451814T1 (es)
SM (1) SMT201400096B (es)
TN (1) TN2011000647A1 (es)
TW (1) TWI421252B (es)
UA (1) UA103930C2 (es)
UY (1) UY32776A (es)
WO (1) WO2011006143A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150082308A (ko) * 2012-11-14 2015-07-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
WO2014078802A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014078813A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
SI3083627T1 (sl) * 2013-12-19 2019-01-31 Novartis Ag Derivati (1,2,4)triazolo(1,5-a)pirimidina kot inhibitorji protozoan proteasoma za zdravljenje parazitskih bolezni, kot je lišmanioza
CA2994027C (en) * 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
US10660334B2 (en) * 2016-08-15 2020-05-26 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
CA3059327A1 (en) * 2017-04-24 2018-11-01 Novartis Ag Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
IL139835A (en) 1998-06-12 2005-11-20 Sod Conseils Rech Applic Imidazolyl derivatives and their use as somatostatin receptor ligands
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
EP1140942B1 (en) 1998-12-31 2004-03-10 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Prenyl transferase inhibitors
RU2298417C2 (ru) 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
DE60128102T2 (de) 2000-08-01 2008-01-03 Societe De Conseils De Recherches Et D`Applications Scientifiques (S.C.R.A.S.) Imidazolderivate
EP1363899B1 (en) * 2001-01-02 2005-05-11 F.Hoffmann-La Roche Ag Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE60316416T2 (de) 2002-03-25 2008-06-26 Merck & Co., Inc. Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
AU2003274565A1 (en) 2002-09-27 2004-04-19 Centre National De Recherche Scientifique Composition for the treatment of nasopharyngeal carcinoma and use thereof
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
JP2006520819A (ja) * 2003-03-06 2006-09-14 メルク　エンド　カムパニー　インコーポレーテッド 抗原虫薬イミダゾピリジン化合物
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
EP1917001A2 (en) 2005-08-11 2008-05-07 F.Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
WO2007124423A2 (en) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
US20120142623A1 (en) 2006-07-07 2012-06-07 Michael Lagunoff Compositions And Methods For Predicting Inhibitors Of Protein Targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
EP2124954A2 (en) 2007-01-26 2009-12-02 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物

Also Published As

Publication number Publication date
HK1164304A1 (en) 2012-09-21
US8557801B2 (en) 2013-10-15
IL217384A (en) 2015-07-30
AU2010271247B2 (en) 2013-07-18
EA201200098A1 (ru) 2012-07-30
US20160108051A1 (en) 2016-04-21
SMT201400096B (it) 2014-09-08
GT201200004A (es) 2014-03-27
HN2012000023A (es) 2014-08-18
CN102471341A (zh) 2012-05-23
TWI421252B (zh) 2014-01-01
BR112012000413B1 (pt) 2022-02-15
TN2011000647A1 (en) 2013-05-24
SG176938A1 (en) 2012-01-30
MY157238A (en) 2016-05-13
US9963454B2 (en) 2018-05-08
EA019655B1 (ru) 2014-05-30
EP2737927A1 (en) 2014-06-04
KR101378666B1 (ko) 2014-03-26
CN102471341B (zh) 2014-07-02
EP2737927B1 (en) 2016-03-30
CU20120002A7 (es) 2012-06-21
BR112012000413A2 (pt) 2020-08-11
ES2477940T3 (es) 2014-07-18
MA33419B1 (fr) 2012-07-03
CO6491060A2 (es) 2012-07-31
WO2011006143A3 (en) 2011-06-09
CA2767664A1 (en) 2011-01-13
HRP20140641T1 (hr) 2014-09-26
NZ597275A (en) 2013-05-31
SI2451814T1 (sl) 2014-08-29
UA103930C2 (ru) 2013-12-10
PT2451814E (pt) 2014-07-16
PE20130399A1 (es) 2013-04-06
JO3156B1 (ar) 2017-09-20
EP2451814A2 (en) 2012-05-16
KR20120047939A (ko) 2012-05-14
CA2767664C (en) 2013-12-10
CR20120008A (es) 2012-03-12
UY32776A (es) 2011-02-28
WO2011006143A2 (en) 2011-01-13
US20110059934A1 (en) 2011-03-10
US9469645B2 (en) 2016-10-18
US20130281403A1 (en) 2013-10-24
PL2451814T3 (pl) 2014-09-30
JP2012532890A (ja) 2012-12-20
EP2451814B1 (en) 2014-04-09
DK2451814T3 (da) 2014-07-14
JP5432376B2 (ja) 2014-03-05
AU2010271247A1 (en) 2012-01-19
AR077463A1 (es) 2011-08-31
MX2012000389A (es) 2012-03-07
TW201105675A (en) 2011-02-16
CU24155B1 (es) 2016-03-31
IL217384A0 (en) 2012-02-29
CL2012000042A1 (es) 2012-12-21
ES2574529T3 (es) 2016-06-20

Similar Documents

Publication Publication Date Title
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
NI201600071A (es) Compuestos de inhibidor de autotaxina
CR20150326A (es) Inhibidores de autotaxina
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
CR20120202A (es) Métodos y composiciones para tratar cáncer
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112014010631A2 (pt) inibidores de pak para o tratamento da síndrome do x frágil
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
GT201200038A (es) Composicion para tratar la fibrosis quistica
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201270728A1 (ru) Пуриновые соединения
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
EA201171414A1 (ru) Ингибиторы белков семейства iap
CO7121334A2 (es) Formulaciones vesiculares
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
BRPI1010072A2 (pt) composição injetavel contendo hidroxicloroquina para administração local para o tratamento de hemorróida
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab
CO6751242A2 (es) Combinación y composición para el tratamiento de obesidad
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad
CY1115356T1 (el) Συντηγμeνες ιμιδαζολες και συνθεσεις περιλαμβανοντας αυτες για την αγωγη παρασιτικων παθησεων, οπως ειναι π.χ. η ελονοσια
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch